Riboscience LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.riboscience.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal CancerAdvanced Colorectal Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Riboscience, LLC.
- Target Recruit Count
- 150
- Registration Number
- NCT06824064
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇻🇳Tam Anh TP. Ho Chi Minh General Hospital, Ho Chi Minh, Ho Chi Minh City, Vietnam
🇻🇳Tam Anh, Ha Noi General Hospital, Ha Noi, Vietnam
Expanded Access RBS2418 Treatment
- Conditions
- Expanded Access in Pancreatic Cancer
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Riboscience, LLC.
- Registration Number
- NCT05683470
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Riboscience, LLC.
- Target Recruit Count
- 164
- Registration Number
- NCT05270213
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
News
No news found